ClinicalTrials.gov
ClinicalTrials.gov Menu

Management of Highly Active Anti-retroviral Therapy-related Hyperlipidemia Among HIV-infected Patients in Taiwan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01697540
Recruitment Status : Completed
First Posted : October 2, 2012
Last Update Posted : August 9, 2018
Sponsor:
Information provided by (Responsible Party):
Kaohsiung Medical University Chung-Ho Memorial Hospital

September 28, 2012
October 2, 2012
August 9, 2018
September 2012
June 27, 2017   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01697540 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Management of Highly Active Anti-retroviral Therapy-related Hyperlipidemia Among HIV-infected Patients in Taiwan
Tropical Medicine Center (TMC), Kaohsiung Medicine University Hospital (KMUH)
  1. Written informed consent must be obtained before any study specific procedures are undertaken.
  2. The process of the experiment (brief describe) The patients must come back for follow during 4 to 12 weeks after starting the new therapy. The investigators will follow the patients' lipid profile and any side effects and stop the observation till 36 months after starting the new therapy. The serum level of HIV-VL, CD4, GOT, GPT, triglyceride, cholesterol, HDL-cholesterol, and LDL-cholesterol will be checked every 3 months. The patients' chart and all data will be delinked to protect the patients' right and privacy.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
HIV/AIDS group
HIV
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
100
Same as current
June 27, 2017
June 27, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • HIV-infected patients who receive HAART therapy but have metabolic side effects.
  • Age over 20 years old

Exclusion Criteria:

  • Abnormal liver function: GOT or GPT 5 times over normal upper limit
Sexes Eligible for Study: All
Child, Adult, Older Adult
No
Contact information is only displayed when the study is recruiting subjects
Taiwan
 
 
NCT01697540
KMUHIRB-2012-05-05(I)
Not Provided
Not Provided
Not Provided
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung Medical University Chung-Ho Memorial Hospital
Not Provided
Not Provided
Kaohsiung Medical University Chung-Ho Memorial Hospital
January 2017